Rift Valley fever virus noncoding regions of L, M and S segments regulate RNA synthesis

Virology
Nicolas GauliardM Bouloy

Abstract

Rift Valley fever virus (RVFV) (Phlebovirus, Bunyaviridae) possesses a genome composed of three negative-stranded RNA molecules. Each segment contains 3' and 5' noncoding regions with terminal complementary sequences forming a panhandle structure. We showed that transcription-replication of the L, M and S segments is regulated, and we established a minigenome rescue system expressing a CAT reporter to investigate the role of the noncoding regions in this process. The L, M and S segment-based minigenomes were shown to drive bona fide transcription and replication and to express variable levels of CAT reporter, indicating differential promoter activities within the noncoding sequences. In addition, we found a good correlation between the relative promoter strength and the abundance of viral RNA species in RVFV-infected cells. Altogether, these results show that RVFV minigenomes are powerful tools to study transcription and replication and constitute a valuable basis to rescue infectious virus from cDNAs.

References

Nov 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·G K McMaster, G G Carmichael
Oct 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M BouloyR M Krug
Aug 1, 1988·Virology·C RossierD Kolakofsky
Aug 11, 1993·Nucleic Acids Research·A ZobelG Hobom
Oct 1, 1996·Virology·K L HutchinsonS T Nichol
Oct 24, 2000·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Mar 19, 2003·Virology·Kirsten FlickRamon Flick
Apr 30, 2003·Journal of Virology·Ramon FlickFredrik Elgh
Jan 15, 2004·Journal of Virology·John N Barr, Gail W Wertz
May 14, 2004·Journal of Virology·Alain KohlRichard M Elliott
May 14, 2005·Journal of Virology·Anice C LowenRichard M Elliott
Sep 22, 2010·Vector Borne and Zoonotic Diseases·Sara MoutaillerAnna-Bella Failloux

❮ Previous
Next ❯

Citations

Jun 1, 2007·Journal of Virology·Tetsuro IkegamiShinji Makino
Jan 30, 2008·PLoS Pathogens·Nicolas Le MayMichèle Bouloy
Dec 29, 2010·Proceedings of the National Academy of Sciences of the United States of America·Kaori TerasakiShinji Makino
Jun 20, 2012·Antiviral Research·Tetsuro Ikegami
May 1, 2007·Veterinary Microbiology·Yohsuke OgawaHiroomi Akashi
Aug 26, 2011·The Journal of General Virology·Cheryl T Walter, John N Barr
Dec 14, 2011·PLoS Neglected Tropical Diseases·Céline GommetJean-Jacques Panthier
Jul 20, 2016·Viruses·Katherine E HornakJ Stephen Lodmell
Aug 23, 2016·PLoS Pathogens·Paul J Wichgers Schreur, Jeroen Kortekaas
Jan 10, 2017·PLoS Neglected Tropical Diseases·Abdallah M SamyMatthew Hall
Jul 29, 2011·Journal of Virology·Benjamin BrennanRichard M Elliott
May 13, 2017·MSphere·Isabelle DietrichStefanie C Becker
Jan 2, 2015·Journal of Virology·Benjamin BrennanRichard M Elliott
Nov 7, 2012·Proceedings of the National Academy of Sciences of the United States of America·Donald D RaymondJanet L Smith
Nov 15, 2018·Virus Genes·Natasha N GaudreaultJuergen A Richt
May 20, 2016·Journal of Virology·Magalie MazelierPierre-Yves Lozach
Dec 31, 2020·International Journal of Molecular Sciences·Corey R NelsonTrushar R Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.